AAD Cross Over Study

The objective of this study is to investigate the correlation between two commonly prescribed antiarrhythmic medications, Flecainide and Sotalol, which are utilized in the treatment of atrial fibrillation. Atrial fibrillation is a condition characterized by the upper chambers of the heart beating in a fast, disorganized rhythm. The study aims to explore the connection between these medications and minor variations in DNA that are present in all individuals.

In order to participate you must meet the following criteria:

• Are at least 18 years of age.
• Are of African, European, and/or Hispanic descent.
• Have a history of typical or early-onset symptomatic (≥2 episodes/month) paroxysmal/persistent AF.
• Have an ECG that was recorded within 1 month of randomization showing AF.
• Are eligible for both Flecainide (Class I) and Sotalol (Class III) AAD.
• Are able to give informed consent.

You will be excluded from the study if any of the following criteria apply to you:

• Have permanent AF or isolated atrial flutter.
• Have had cardiac or thoracic surgery within the previous 6 months.
• Have a history of prior AF ablation.
• Have already been tried on 2 or more AADs in the past for AF.
• Have left ventricular ejection fraction < 50%.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.